{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:04:49Z","timestamp":1792047889429,"version":"4.4.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The 9q22.3 syndrome is an autosomal dominant microdeletion syndrome with similarities to Gorlin syndrome (GS). It encompasses the <jats:italic toggle=\"yes\">PTCH1<\/jats:italic> gene locus that harbors mutations for GS. Although the 9q22.3 syndrome is associated with Wilms tumor (WT), WT is not a GS-associated tumor, implying a different mechanism involving <jats:italic toggle=\"yes\">PTCH1<\/jats:italic>, or a different locus in the 9q22.3 region. The goal of this study is to report the association between WT and 9q22.3 syndrome and review the outcome of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Observations:<\/jats:title>\n            <jats:p>We report 2 new cases of WT with 9q22.3 deletion and review the literature. Among the 44 described patients with 9q22.3 deletion, 7 developed WT (16%) at a mean age of 45 months (range, 4 to 84\u2009mo). All patients had dysmorphic features, macrocephaly, and developmental delay, and there was an association with overgrowth (4\/7). One patient had bilateral WT, another had a synchronous rhabdomyosarcoma. The outcome was excellent with all cases reported to be in complete remission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The 9q22.3 microdeletion syndrome should be considered at diagnosis of WT in children with dysmorphic features. Conversely, patients with a known 9q22.3 deletion syndrome should be considered for a WT predisposition surveillance program, especially those with overgrowth. The management should be individualized and given the excellent prognosis, and the unknown future risk of metachronous disease or other malignancy, the surgical approach should be carefully considered.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000001322","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T19:20:16Z","timestamp":1540581616000},"page":"e517-e520","source":"Crossref","is-referenced-by-count":5,"title":["Wilms Tumor Associated With the 9q22.3 Microdeletion Syndrome: 2 New Case Reports and a Review of The Literature"],"prefix":"10.1097","volume":"41","author":[{"given":"Julie","family":"Cayrol","sequence":"first","affiliation":[{"name":"Children\u2019s Cancer Centre"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nightingale","sequence":"additional","affiliation":[{"name":"Paediatric Surgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Challis","sequence":"additional","affiliation":[{"name":"Victorian Clinical Genetics Services, Murdoch Children\u2019s Research Institute, Melbourne, Vic., Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Campbell","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Children\u2019s Cancer Centre"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Heloury","sequence":"additional","affiliation":[{"name":"Paediatric Urology, The Royal Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"A(2)","key":"R1-20230918","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajmg.a.34216","article-title":"Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia, and developmental delay","volume":"158","author":"Muller","year":"2012","journal-title":"Am J Med Genet Part A"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.ejhg.5201613","article-title":"Interstitial 9q22.3 microdeletion: clinical and molecular characterisation of a newly recognised overgrowth syndrome","volume":"14","author":"Redon","year":"2006","journal-title":"Eur J Hum Genet"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/ajmg.a.34128","article-title":"Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)","volume":"155","author":"Bree","year":"2011","journal-title":"Am J Med Genet Part A"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1399-0004.2008.01141.x","article-title":"Clinical features of microdeletion 9q22.3 (pat)","volume":"75","author":"Shimojima","year":"2009","journal-title":"Clin Genet"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/ajmg.a.36259","article-title":"Multiple tumor types including leiomyoma and Wilms tumor in a patient with Gorlin syndrome due to 9q22.3 microdeletion encompassing the PTCH1 and FANC-C loci","volume":"161","author":"Garavelli","year":"2013","journal-title":"Am J Med Genet Part A"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ncponc0608","article-title":"Reyes-mugica m. rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome","volume":"3","author":"Cajaiba","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ejhg.2012.252","article-title":"Wilms&rsquo; tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas","volume":"21","author":"Isidor","year":"2013","journal-title":"Eur J Hum Genet"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S0140-6736(14)62395-3","article-title":"Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms\u2019 tumour (SIOP WT 2001): An open-label, non-inferiority, randomised controlled trial","volume":"386","author":"Pritchard-Jones","year":"2015","journal-title":"Lancet"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajmg.a.38142","article-title":"Childhood cancer predisposition syndromes\u2014a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology","volume":"173","author":"Ripperger","year":"2017","journal-title":"Am J Med Genet Part A"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2340\/00015555-2822","article-title":"9q22.3 microdeletion syndrome with multiple basal cell carcinomas treated with vismodegib: three key messages in one patient","volume":"98","author":"Kieny","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"D1","key":"R12-20230918","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: Somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/pbc.22881","article-title":"Long-term outcome of bilateral Wilms Tumors (BWT)","volume":"56","author":"Aronson","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrurol.2017.163","article-title":"Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","volume":"14","author":"Van Den Heuvel-Eibrink","year":"2017","journal-title":"Nat Rev Urol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:20:05Z","timestamp":1695010805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001322","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}